DiagnosTear Technologies, Inc.

As of June 30, 2026, DiagnosTear Technologies, Inc. carries a market capitalization of 19.47M, placing it among publicly traded companies globally. Its enterprise value stands at 19.10M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, DiagnosTear Technologies, Inc. has 60.84M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, DiagnosTear Technologies, Inc. maintains a current ratio of 1.66, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities.

As of the close on October 19, 2026, DiagnosTear Technologies, Inc.'s stock has declined approximately 31.82% over the past 52 weeks. The 50-day moving average sits at 0.28, while the 200-day moving average is 0.40.

As of June 30, 2026, DiagnosTear Technologies, Inc. holds 524,000.00 in cash and equivalents against 152,000.00 in total debt, resulting in a net debt position of -514,000.00. Total book value stands at 1.55M, with working capital of 218,000.00 providing operational flexibility.